Best Nephrology Journals (2026): Ranked by Impact and Accessibility
A ranked guide to the top 12 nephrology journals by impact factor, acceptance rate, APC, and review time, from JASN and Kidney International to accessible open-access options.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Nephrology sits at an interesting crossroads in academic publishing. The field covers everything from basic glomerular biology to dialysis outcomes, transplant immunology, and electrolyte physiology. That breadth means the journal landscape is surprisingly varied, with some titles favoring clinical trials, others prioritizing translational science, and a handful focusing almost exclusively on basic mechanisms. Choosing the right journal isn't just about impact factor. It's about matching your manuscript's scope, methodology, and clinical relevance to a journal that actually wants what you're offering.
The nephrology publishing world has also shifted meaningfully toward open access in recent years. Society journals like Kidney360 and Kidney International Reports have given researchers solid OA options that didn't exist a decade ago. Meanwhile, the top-tier titles remain fiercely competitive, with acceptance rates below 10% at journals like JASN and Kidney International.
Quick Answer: Top 5 Nephrology Journals
If you're short on time, here are the top picks depending on what you need:
- Nature Reviews Nephrology (IF ~39.8) for high-impact reviews and perspectives
- Journal of the American Society of Nephrology (JASN) (IF ~14.6) for top-tier original research
- Kidney International (IF ~12.4) for strong clinical and translational work
- American Journal of Kidney Diseases (AJKD) (IF ~10.2) for clinical nephrology and guidelines
- Clinical Journal of the American Society of Nephrology (CJASN) (IF ~8.1) for practical clinical research
Full Comparison Table
Journal | IF | Acceptance Rate | APC | Review Time | Scope |
|---|---|---|---|---|---|
Nature Reviews Nephrology | ~36.2 | <5% | $11,390 (OA option) | 4-8 weeks | Reviews, perspectives |
JASN | ~14.6 | ~8% | $3,500 (OA option) | 6-10 weeks | Original research, all nephrology |
Kidney International | ~12.4 | ~10% | $5,200 (OA option) | 4-8 weeks | Clinical and translational |
AJKD | ~10.2 | ~12% | Subscription | 6-10 weeks | Clinical nephrology |
CJASN | ~8.1 | ~15% | $2,800 (OA option) | 4-8 weeks | Clinical research |
Nephrology Dialysis Transplantation | ~6.1 | ~18% | $3,800 (OA option) | 6-12 weeks | European clinical nephrology |
American Journal of Nephrology | ~4.3 | ~25% | $3,150 (OA) | 4-6 weeks | Clinical research |
Kidney International Reports | ~3.8 | ~30% | $2,900 (OA) | 4-8 weeks | Open access, broad scope |
Kidney360 | ~3.5 | ~35% | $2,500 (OA) | 4-6 weeks | Open access, ASN journal |
Nephron | ~2.8 | ~35% | $2,600 (OA option) | 6-10 weeks | Experimental and clinical |
Clinical Kidney Journal | ~3.4 | ~30% | Free OA | 4-8 weeks | Clinical nephrology, European |
BMC Nephrology | ~2.1 | ~40% | $2,490 (OA) | 6-10 weeks | Broad clinical nephrology |
Elite Tier: The Hardest to Crack
Nature Reviews Nephrology
This is the highest-impact title in nephrology, but it's almost entirely review and commentary content. You won't submit original research here. Instead, you'll need an invitation or a very compelling pitch for a review article. The readership is broad, and a publication here will get noticed across medicine, not just within nephrology. If you've been invited to write a review, take it seriously.
Journal of the American Society of Nephrology (JASN)
JASN is the flagship for original nephrology research in the US. It publishes across the full spectrum, from basic science to clinical epidemiology, but it favors work that connects mechanisms to clinical outcomes. The review process is thorough and usually constructive, though turnaround can stretch to 10 weeks. If your study changes how we understand a kidney disease or its treatment, JASN should be your first stop.
Kidney International
Kidney International is JASN's main rival and the top-tier journal of the International Society of Nephrology. It leans slightly more toward translational and clinical work compared to JASN's broader basic science coverage. European and international authors sometimes find a warmer reception here. The journal has a well-organized review process and provides detailed feedback even on rejected manuscripts.
Strong Tier: Competitive but Realistic
American Journal of Kidney Diseases (AJKD)
AJKD is the clinical nephrology workhorse. It's the go-to for observational studies, clinical guidelines, and case-based teaching. If your paper is clinically oriented and practice-changing, AJKD is an excellent fit. It doesn't publish much basic science, so don't send your mouse model studies here. The readership is largely practicing nephrologists, which means your work will actually influence clinical decisions.
Clinical Journal of the American Society of Nephrology (CJASN)
CJASN fills the gap between JASN and more accessible journals. It's selective but not impossibly so, and it values well-designed clinical studies, quality improvement research, and educational content. Review turnaround is faster than JASN on average. This is a strong choice for mid-career researchers building a clinical research portfolio.
Nephrology Dialysis Transplantation (NDT)
NDT is the ERA's flagship journal and carries significant weight in European nephrology. It publishes a mix of clinical and translational research with a slight European bias in terms of study populations and healthcare system relevance. The review process can be slower than some competitors, but the editorial team provides substantive feedback. If your work addresses dialysis outcomes or transplant immunology, NDT should be on your shortlist.
American Journal of Nephrology
This journal sits in a solid mid-range position. It's a reasonable target for well-executed clinical studies that may not have the novelty for JASN or Kidney International but still contribute meaningfully to the literature. Turnaround is relatively quick, and the acceptance rate around 25% makes it realistic for many research groups.
Accessible Tier: Solid Options for Broader Research
Kidney International Reports
This is Kidney International's open access companion, and it's built a solid reputation quickly. It publishes work that's scientifically sound but may not reach the novelty threshold for the parent journal. The OA model means wider dissemination, and the connection to the ISN adds credibility. A good option for replication studies, secondary analyses, and regional cohort studies.
Kidney360
ASN launched Kidney360 as a fully open access journal, and it's become a credible home for nephrology research at various levels. The acceptance rate is more forgiving, and the review process tends to be constructive rather than adversarial. It's particularly welcoming to quality improvement projects, educational innovations, and studies from smaller centers.
Clinical Kidney Journal
CKJ deserves special attention because it offers free open access publishing with no APC. That's rare and valuable. The journal is ERA-affiliated and indexed in all major databases. Quality is consistent, and the review process is fair. If you need an OA publication without the financial burden, CKJ is a standout choice.
BMC Nephrology
BMC Nephrology is part of the BMC family with a straightforward OA model. It focuses on scientific soundness rather than perceived novelty, which means well-designed studies that confirm or refute existing findings can find a home here. The acceptance rate around 40% reflects this inclusive approach. It's a reasonable option for pilot studies, negative results, and methodological papers.
Decision Framework: Matching Your Paper to the Right Journal
If your paper is a large multicenter RCT with practice-changing results, send it to JASN or Kidney International first. These are the venues where landmark trials get the attention they deserve.
If your paper is a well-designed observational study with clinical implications, AJKD or CJASN are strong fits. Both value clinical relevance over flashy mechanisms.
If your paper is translational, bridging bench and bedside, Kidney International or JASN will be most receptive. Both journals appreciate work that connects molecular findings to patient outcomes.
If your paper is a single-center cohort study or pilot trial, Kidney International Reports, Kidney360, or American Journal of Nephrology offer realistic targets without sacrificing credibility.
If you're an early-career researcher building your CV, consider Kidney360 or Clinical Kidney Journal. Both provide good visibility and a supportive review process, and CKJ won't cost you anything for OA publication.
If your paper focuses on dialysis or transplant outcomes, NDT should be near the top of your list, especially if your data comes from European populations.
Common Mistakes in Nephrology Journal Selection
Sending basic science to clinical journals. AJKD and CJASN are clinical titles. If your paper is primarily about molecular mechanisms in podocytes, they'll desk-reject it before it reaches a reviewer. Match the journal's scope to your methods.
Ignoring geographic fit. NDT and CKJ have European leanings. If your study involves a US Medicare cohort, JASN or CJASN may be more natural homes. Conversely, European registry studies often land well at NDT.
Overlooking society journals. Many researchers fixate on impact factor and miss the audience question. A paper in AJKD might change clinical practice for thousands of nephrologists. The same paper in a general medical journal might get a higher IF but reach fewer specialists.
Underestimating open access companions. Kidney International Reports and Kidney360 aren't dumping grounds for rejected papers. They have real review processes and growing readership. Publishing there isn't a consolation prize.
Submitting without pre-submission inquiry. For elite-tier journals, a brief pre-submission inquiry can save you months. JASN and Kidney International both respond to these, and a positive signal gives you confidence before investing in full formatting.
Not checking recent issues. Browse the last six months of your target journal. If they just published three papers on your exact topic, they may have saturation fatigue. Alternatively, if they've published nothing in your area, it might not be in scope.
Before You Submit
Getting your manuscript into the right nephrology journal takes more than good science. It takes strategic formatting, polished writing, and alignment with journal expectations. Before you hit submit, consider running your paper through Manusights' AI review tool to catch formatting issues, flag potential reviewer objections, and make sure your abstract and methods section meet the standards of your target journal. It's a small step that can save you a round of revisions or, worse, a desk rejection that costs you months in the publication timeline.
Sources
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.